Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of intravitreal vamikibart in uveitic macular edema
CTR20243660Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of vamikibart in uveitic macular edema (UME), sponsored by Roche. Started Sep 2024; status: completed.
02
Drugs
vamikibart
03
Conditions
uveitic macular edema (UME)
Beyond the preview
Go deeper on CTR20243660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243660.